About Norris Medicines
Norris Medicines is a publicly listed company based in Ankleshwar (India) founded in 1990. Non-sterile and sterile dosage formulations are manufactured and exported. The company has 18 employees. Its chief executive, as recorded, is Vimal Shah. Its Indian entity Norris Medicines Limited reported revenue of ₹8.18 Cr. Norris Medicines offers products and services including Antibiotic Range, Antiinflammatory-pain-management, Anti Emetic, Nutrition, and G.I.Range. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and Formulation. Similar companies include Akums, Jubilant Life Sciences and Nectar Lifesciences; 2 of its 3 listed similar companies have raised funding.
Company details
Norris Medicines is a manufacturer exporter of pharmaceutical medicines. The company is specialized in the production of non-sterile dosage (tablets, capsules, liquid orals, ointments, dry syrups) as well as sterile dosage in form of ampoules vials. The products portfolio covers antibiotics, anti Inflammatory, dermatology, nutrition, gastro, antimalarial, dental, diabetic cardiac medicines. The company has WHO cGMP certified manufacturing plants. The company also engaged in franchise marketing, contractual manufacturing export businesses. The clients in contract manufacturing are Novartis, Sandoz, Abbott, Themis Medicare JBCPL.
- Headquarters Ankleshwar, India
- Employees 18
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website norrispharma.com
- Social LinkedIn
- Legal Name Norris Medicines Ltd.
- Market Cap₹14.26 Cr
NORRIS · BSE
- Share Price₹14.16
-0.70% today
- Revenue₹8.13 Cr
FY 2025-26 · +39.7% YoY
- EBITDA₹0.66 Cr
Margin 8.1%
- Net Profit−₹0.28 Cr
FY 2025-26 · +77.4% YoY
- Employee Count18
Associated legal entities of Norris Medicines
Norris Medicines operates through Norris Medicines Limited, a listed company (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Norris Medicines Limited Listed CIN L24230GJ1990PLC086581 | Active | 07 Sep 1990 | Ankleshwar, Gujarat | ₹8.2 Cr | 18 | 5 | View details |
Products & Services of Norris Medicines
Norris Medicines offers a comprehensive portfolio of products and services, including Antibiotic Range, Antiinflammatory-pain-management, Anti Emetic, Nutrition, and G.I.Range.
Range of antibiotics for treating bacterial infections effectively.
Products for managing pain and inflammation in various conditions.
Medications to control nausea and vomiting symptoms.
Nutritional supplements for health and dietary support.
Formulations for gastrointestinal disorders and digestive health.
Board of directors of Norris Medicines Limited (Norris Medicines)
Norris Medicines Limited is the primary company behind Norris Medicines. The board of Norris Medicines Limited currently have 3 directors; the longest-serving is Vimal Dhirendra Shah, appointed in 2023. 14 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Vimal Dhirendra Shah DIN 01506655 | Director | 29 Dec 2023 | 2 yrs 10 mo | Norris Medicines Limited |
| Angamuthu Vadivel DIN 10581538 | Director | 29 Apr 2024 | 2 yrs 6 mo | Norris Medicines Limited |
| Praveenchand Bafna DIN 06538685 | Director | 24 Aug 2024 | 2 yrs 2 mo | Norris Medicines Limited |
People of Norris Medicines
1 people are tracked at Norris Medicines (1 in leadership); the tracked headcount is 18.
| Name | Role | Group |
|---|---|---|
| CEO & MD | Leadership |
Complete people profiles for Norris Medicines
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Norris Medicines
Norris Medicines is a publicly listed company on the BSE with ticker symbol NORRIS in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date21 Mar 2018
- Listed onBSE: 524414
- Listed entityNorris Medicines Ltd.
- Exchange sectorHealth technology
- ISININE744C01029
- Share price₹15.74 (+4.93% on the day) · 2026-10-13
- Volume (last session)247
Financials of Norris Medicines
Exchange-reported figures of Norris Medicines Limited, the listed company behind Norris Medicines (BSE: NORRIS).
Financial Highlights
FY 2025-26 · StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 8.13 | 5.82 | 5.64 | 8.36 | 9.44 | 12.25 | 7.84 |
| Revenue growth | +39.7% | +3.2% | -32.5% | -11.4% | -22.9% | +56.3% | - |
| EBITDA | 0.66 | (0.26) | (0.17) | 0.93 | (0.07) | (1.74) | (2.16) |
| EBITDA margin | +8.1% | -4.5% | -3.0% | +11.1% | -0.7% | -14.2% | -27.6% |
| Profit before tax | (0.28) | (1.18) | (1.08) | (1.19) | (2.18) | (3.99) | (3.68) |
| Net profit | (0.28) | (1.24) | (1.15) | (1.75) | (3.26) | (4.96) | (2.84) |
| Net profit margin | -3.4% | -21.3% | -20.4% | -20.9% | -34.5% | -40.5% | -36.2% |
| EPS (₹) | (0.28) | (1.25) | (1.20) | (1.76) | (3.29) | (5.00) | (2.86) |
| Balance sheet | |||||||
| Total assets | 6.39 | 6.71 | 7.89 | 8.96 | 10.38 | 8.09 | 15.45 |
| Net worth | (15.14) | (14.86) | (13.63) | (12.44) | (10.69) | (7.43) | (2.46) |
| Total debt | 21.53 | 21.58 | 21.52 | 21.40 | 21.08 | 15.52 | 17.92 |
| Cash & bank | 0.02 | 0.04 | 0.04 | 0.02 | 0.02 | 0.02 | 0.06 |
| Net working capital | (0.69) | (0.75) | (0.15) | 0.20 | 0.46 | (3.46) | 2.33 |
| Cash flow | |||||||
| Cash from operations | 0.59 | 0.51 | 0.17 | 1.20 | (1.01) | 1.11 | (2.88) |
| Cash from investing | (0.09) | 0.00 | 0.05 | (0.02) | (0.09) | (0.06) | 0.00 |
| Cash from financing | (0.52) | (0.50) | (0.20) | (1.18) | 1.10 | (1.09) | 2.86 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.92 | 1.41 | 3.27 | 2.00 | 1.46 | 2.72 | 1.11 | 1.27 |
| Revenue growth (YoY) | -37.0% | -48.2% | +194.6% | +57.5% | +102.8% | - | - | - |
| Other income | 0.00 | 0.02 | 0.00 | 0.00 | 0.02 | 0.05 | 0.00 | 0.00 |
| Total expenses | 1.21 | 1.10 | 2.32 | 2.49 | 1.56 | 2.65 | 1.13 | 1.41 |
| EBITDA | (0.29) | 0.31 | 0.95 | (0.49) | (0.10) | 0.07 | (0.02) | (0.14) |
| EBITDA margin | -31.5% | +22.0% | +29.1% | -24.5% | -6.8% | +2.6% | -1.8% | -11.0% |
| Depreciation | 0.11 | 0.12 | 0.12 | 0.12 | 0.12 | 0.14 | 0.13 | 0.13 |
| Interest | 0.00 | 0.15 | 0.13 | 0.11 | 0.11 | 0.15 | 0.12 | 0.08 |
| Profit before tax | (0.40) | 0.06 | 0.70 | (0.72) | (0.31) | (0.17) | (0.27) | (0.35) |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 | 0.00 | 0.00 |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.92 | 1.41 | 3.27 | 2.00 | 1.46 | 2.72 | 1.11 | 1.27 |
| Revenue growth (YoY) | -37.0% | -48.2% | +194.6% | +57.5% | +102.8% | - | - | - |
| Other income | 0.00 | 0.02 | 0.00 | 0.00 | 0.02 | 0.05 | 0.00 | 0.00 |
| Total expenses | 1.21 | 1.10 | 2.32 | 2.49 | 1.56 | 2.65 | 1.13 | 1.41 |
| EBITDA | (0.29) | 0.31 | 0.95 | (0.49) | (0.10) | 0.07 | (0.02) | (0.14) |
| EBITDA margin | -31.5% | +22.0% | +29.1% | -24.5% | -6.8% | +2.6% | -1.8% | -11.0% |
| Depreciation | 0.11 | 0.12 | 0.12 | 0.12 | 0.12 | 0.14 | 0.13 | 0.13 |
| Interest | 0.00 | 0.15 | 0.13 | 0.11 | 0.11 | 0.15 | 0.12 | 0.08 |
| Profit before tax | (0.40) | 0.06 | 0.70 | (0.72) | (0.31) | (0.17) | (0.27) | (0.35) |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 | 0.00 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 8.13 | 5.82 | 5.64 | 8.36 | 9.44 | 12.25 | 7.84 |
| Revenue growth | +39.7% | +3.2% | -32.5% | -11.4% | -22.9% | +56.3% | - |
| Other income | 0.05 | 0.06 | 0.03 | 0.01 | 0.03 | 0.05 | 0.09 |
| Total expenses | 7.47 | 6.08 | 5.81 | 7.43 | 9.51 | 13.99 | 10.00 |
| Employee cost | 0.00 | 1.41 | 1.82 | 2.30 | 2.33 | 3.10 | 3.23 |
| EBITDA | 0.66 | (0.26) | (0.17) | 0.93 | (0.07) | (1.74) | (2.16) |
| EBITDA margin | +8.1% | -4.5% | -3.0% | +11.1% | -0.7% | -14.2% | -27.6% |
| Depreciation | 0.49 | 0.54 | 0.57 | 0.63 | 0.66 | 0.67 | 0.73 |
| Interest | 0.50 | 0.44 | 0.37 | 1.50 | 1.48 | 1.63 | 0.88 |
| Profit before tax | (0.28) | (1.18) | (1.08) | (1.19) | (2.18) | (3.99) | (3.68) |
| Tax | 0.00 | 0.06 | 0.09 | 0.56 | 1.08 | 0.97 | (0.84) |
| Net profit | (0.28) | (1.24) | (1.15) | (1.75) | (3.26) | (4.96) | (2.84) |
| Net profit margin | -3.4% | -21.3% | -20.4% | -20.9% | -34.5% | -40.5% | -36.2% |
| EPS (₹) | (0.28) | (1.25) | (1.20) | (1.76) | (3.29) | (5.00) | (2.86) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 |
| Reserves & surplus | (25.07) | (24.79) | (23.56) | (22.37) | (20.62) | (17.36) | (12.39) |
| Shareholders' funds (net worth) | (15.14) | (14.86) | (13.63) | (12.44) | (10.69) | (7.43) | (2.46) |
| Secured loans | 3.02 | 3.05 | 2.99 | 3.24 | 3.42 | 0.57 | 2.94 |
| Unsecured loans | 18.51 | 18.53 | 18.53 | 18.16 | 17.66 | 14.95 | 14.98 |
| Total debt | 21.53 | 21.58 | 21.52 | 21.40 | 21.08 | 15.52 | 17.92 |
| Total liabilities | 6.39 | 6.71 | 7.89 | 8.96 | 10.38 | 8.09 | 15.45 |
| Assets | |||||||
| Gross block | 27.77 | 27.76 | 27.74 | 27.95 | 27.92 | 27.87 | 27.78 |
| Net block | 4.79 | 5.27 | 5.78 | 6.47 | 7.07 | 7.67 | 8.25 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Inventories | 3.98 | 4.13 | 4.33 | 3.20 | 2.42 | 5.10 | 4.01 |
| Sundry debtors | 1.17 | 1.41 | 1.06 | 1.10 | 1.09 | 1.79 | 2.76 |
| Cash & bank balances | 0.02 | 0.04 | 0.04 | 0.02 | 0.02 | 0.02 | 0.06 |
| Loans & advances | 0.64 | 0.77 | 0.71 | 0.60 | 0.74 | 1.32 | 0.61 |
| Total current assets | 5.81 | 6.35 | 6.14 | 4.92 | 4.27 | 8.23 | 7.44 |
| Total current liabilities | 6.50 | 7.10 | 6.29 | 4.72 | 3.81 | 11.69 | 5.11 |
| Net working capital | (0.69) | (0.75) | (0.15) | 0.20 | 0.46 | (3.46) | 2.33 |
| Total assets | 6.39 | 6.71 | 7.89 | 8.96 | 10.38 | 8.09 | 15.45 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.04 | 0.04 | 0.02 | 0.02 | 0.02 | 0.06 | 0.08 |
| Net cash from operating activities | 0.59 | 0.51 | 0.17 | 1.20 | (1.01) | 1.11 | (2.88) |
| Net cash from investing activities | (0.09) | 0.00 | 0.05 | (0.02) | (0.09) | (0.06) | 0.00 |
| Net cash from financing activities | (0.52) | (0.50) | (0.20) | (1.18) | 1.10 | (1.09) | 2.86 |
| Net change in cash | (0.02) | 0.00 | 0.02 | 0.00 | 0.00 | (0.04) | (0.02) |
| Closing cash | 0.02 | 0.04 | 0.04 | 0.02 | 0.02 | 0.02 | 0.06 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +39.7% | +3.2% | -32.5% | -11.4% | -22.9% | +56.3% | - |
| EBITDA growth | +353.9% | -52.9% | -118.3% | +1428.6% | +96.0% | +19.4% | - |
| PBT growth | +76.3% | -9.3% | +9.2% | +45.4% | +45.4% | -8.4% | -81.3% |
| Net income growth | +77.4% | -7.8% | +34.3% | +46.3% | +34.3% | -74.7% | - |
| Revenue CAGR (3Y) | -0.9% | -14.9% | -22.8% | +2.2% | -16.6% | -3.4% | -27.4% |
| EBITDA CAGR (3Y) | -10.8% | +54.9% | -53.9% | - | -51.9% | -3.1% | +200.0% |
| Profitability & leverage | |||||||
| Net income margin | -3.4% | -21.3% | -20.7% | -20.9% | -34.5% | -40.5% | -36.2% |
| Return on capital employed | - | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Return on net worth | - | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Debt / equity | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-term debt / equity | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | 294.12 | -55.00 | -50.00 | 500.00 | -202.74 | -67.63 | -30.45 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 0.21 | 0.20 | 0.30 | 0.34 | 0.44 | 0.28 |
| Inventory turnover | - | 1.38 | 1.50 | 2.98 | 2.51 | 2.69 | 2.03 |
| Debtors turnover | - | 4.71 | 5.22 | 7.63 | 6.56 | 5.38 | 2.74 |
| EPS (₹) | (0.28) | (1.25) | (1.20) | (1.76) | (3.29) | (5.00) | (2.86) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | (14.98) | (13.73) | (12.54) | (10.77) | (7.49) | (2.49) |
Similar companies to Norris Medicines
Norris Medicines has 3 listed similar companies in our database, 2 of them funded. They include Akums, Jubilant Life Sciences and Nectar Lifesciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| akums.in | 2004 | Delhi, India | $70M | 395 | CDMO focusing on spectrum of dosage forms and therapeutic segments | |
| jubl.com | 1978 | Noida, India | Company offering a suite of R&D and manufacturing services for small molecules and generics | |||
| neclife.com | 1995 | Chandigarh, India | $46.85M | 175 | Cephalosporin APIs and generic formulations are manufactured. |
Detailed similar companies of Norris Medicines
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Norris Medicines (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 2,062 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 548 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 557 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Norris Medicines
Complete news archive for Norris Medicines
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Norris Medicines
Norris Medicines was founded in 1990.
Norris Medicines is headquartered in Ankleshwar, India. It is registered at Ankleshwar, Gujarat, India.
Vimal Shah is the CEO of Norris Medicines, as recorded in our data.
Norris Medicines has 18 employees.
The primary company behind Norris Medicines, Norris Medicines Limited, reported revenue of ₹8.18 Cr for FY 2026, up 40% year on year.
Norris Medicines is a manufacturer exporter of pharmaceutical medicines. The company is specialized in the production of non-sterile dosage (tablets, capsules, liquid orals, ointments, dry syrups) as well as sterile dosage in form of ampoules vials. The products portfolio covers antibiotics, anti Inflammatory, dermatology, nutrition, gastro, antimalarial, dental, diabetic cardiac medicines. The company has WHO cGMP certified manufacturing plants. The company also engaged in franchise marketing, contractual manufacturing export businesses. The clients in contract manufacturing are Novartis, Sandoz, Abbott, Themis Medicare JBCPL.
Norris Medicines's top competitors include Jubilant Life Sciences, Akums and Nectar Lifesciences.
Norris Medicines offers Antibiotic Range, Antiinflammatory-pain-management, Anti Emetic, Nutrition, and G.I.Range.
Yes, Norris Medicines is publicly traded on BSE under the ticker symbol NORRIS.
Norris Medicines operates through Norris Medicines Limited.
The legal entities of Norris Medicines currently have 5 directors, including Iqubal Ismail Patel, Vimal Dhirendra Shah, Praveenchand Bafna and others.